OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.
IPO Year: 2015
Exchange: NASDAQ
Website: opgen.com
4 - OPGEN INC (0001293818) (Issuer)
10-Q - OPGEN INC (0001293818) (Filer)
NT 10-Q - OPGEN INC (0001293818) (Filer)
8-K - OPGEN INC (0001293818) (Filer)
8-K - OPGEN INC (0001293818) (Filer)
10-Q - OPGEN INC (0001293818) (Filer)
10-Q/A - OPGEN INC (0001293818) (Filer)
8-K - OPGEN INC (0001293818) (Filer)
8-K - OPGEN INC (0001293818) (Filer)
NT 10-Q - OPGEN INC (0001293818) (Filer)
8-K - OPGEN INC (0001293818) (Filer)
4 - OPGEN INC (0001293818) (Issuer)
3 - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
4/A - OPGEN INC (0001293818) (Issuer)
4/A - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
4 - OPGEN INC (0001293818) (Issuer)
HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00
Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously
Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously
SC 13D/A - OPGEN INC (0001293818) (Subject)
SC 13D/A - OPGEN INC (0001293818) (Subject)
SC 13D/A - OPGEN INC (0001293818) (Subject)
SC 13D - OPGEN INC (0001293818) (Subject)
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number: 1-877-704-4453 International Dial-in Number: 1-201-389-0920 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6 Re
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th, 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call DetailsU.S. Dial-in Number:International Dial-in Number:Webcast: 1-877-704-44531-201-389-0920https://viavid.webcasts.com/starthere.jsp?ei=1611539&tp_key=76976884dc Replay Details U.S. Dial-in Number:
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Wednesday, March 29th, 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-704-4453 International Dial-in Number:1-201-389-0920 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1595064&tp_key=d21054e901 Conference I
Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platformElects Yvonne Schlaeppi as new, independent non-executive director to the boardManagement conference call scheduled for November 10, 2022, at 4:30 p.m. EST ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Managemen
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Standard Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-704-4453 International Dial-in Number:1-201-389-0920 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1569725&tp_key=91a31a2b1f Conference ID:1373
Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022Requested additional 180-day period to regain compliance with Nasdaq minimum bid price ruleManagement conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results. Management will host an investor call to discuss quarter
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. financial markets on Thursday, August 11th, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call DetailsU.S. Dial-in Number:1-877-704-4453International Dial-in Number:1-201-389-0920Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1556114&tp_key=e1546ec0f5Conference ID:13730742 Replay De
Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. "We are excited about our 2022 progress to date, as we continue to achieve our key milestones," said Oliver Schacht, Presid
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by
Gainers Akili (NASDAQ:AKLI) stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. The company's market cap stands at $31.4 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51.83% to $2.06. The company's market cap stands at $2.7 million. Eliem Therapeutics (NASDAQ:ELYM) shares rose 50.0% to $7.53. The company's market cap stands at $208.7 million. GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 45.99% to $16.06. The market value of their outstanding shares is at $418.4 million. The company's, Q1 earnings came out yesterday. Dare Bioscience (NASDAQ:DARE) stock moved upwards by 22.75% to $0.35. The company's market cap stands at $34.8 million. Lucid Diagnostic
OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Ares Genetics' insolvency proceedings. Since the sales of bot
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares increased by 9.93% to $0.82. The market value of their outstanding shares is at $22.2 million. Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 9.19% to $24.59. The company's market cap stands at $1.0 billion. Matinas BioPharma Hldgs (AMEX:MTNB) stock increased by 8.16% to $0.4. The company's market cap stands at $86.9 million. The company's, Q4 earnings came out 3 days ago. Ontrak (NASDAQ:OTRK) shares rose 7.86% to $0.48. The company's market cap stands at $13.2 million. Apollomics (
- SEC Filing
ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all
ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special
ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Are
ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the "SEC"). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable e
David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock ("Series E Preferred Stock") of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstan
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis GmbH in Germany and Ares Genetics GmbH in Austria filed for insolvency under German and Austrian laws, respectively, in November 2023 ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (N
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company"), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the "Existing Warrants"), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per shar
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f
Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICsNext phase to cover full AMR assay and cartridge development, analytical testing and software developmentRelated payments of up to approximately $0.6 million will bring total collaboration commitment to date to approximately $1.5 million ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has signed an extended and co
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number: 1-877-704-4453 International Dial-in Number: 1-201-389-0920 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6 Re